In brief
As drug-resistant infections claim thousands of lives annually in India, new locally-developed antibiotics like Enmetazobactam and Zaynich are showing promise in the fight against these formidable pathogens. Medical experts stress the need for comprehensive reforms in prescribing practices and healthcare policies to effectively combat antibiotic resistance.
India is on the frontline of the battle against drug-resistant infections, particularly as the prevalence of superbugs continues to rise alarmingly. Antibiotics, once hailed as miracles of modern medicine, are increasingly losing their effectiveness due to bacteria that have evolved to outsmart these crucial drugs. The statistics are staggering; according to The Lancet, drug-resistant infections led to a staggering 1.14 million deaths globally in 2021, with India suffering significantly, accounting for around 300,000 deaths in 2019 alone, as antibiotic-resistant infections ravaged the populace.Among the challenges posed by these "superbugs," the rise of antibiotic resistance has become a pressing concern for healthcare professionals dealing with critically ill patients. Encouragingly, innovative drug developments are emerging from India, aiming to counteract this serious threat. One standout is Enmetazobactam, the first antibiotic developed in India to receive approval from the U.S. Food and Drug Administration (FDA). This injectable drug is specifically designed to treat severe infections such as urinary tract infections, pneumonia, and bloodstream infections. By targeting the defense mechanisms of bacteria rather than directly attacking the bacteria, Enmetazobactam can effectively neutralize harmful enzymes like beta-lactamase that would otherwise destroy antibiotics. As a result, it helps maintain the efficacy of existing last-resort antibiotics.Mumbai-based Wockhardt is also making strides with their new antibiotic, Zaynich, which is currently in its Phase-3 trials. Dr. Habib Khorakiwala, the founder chairman of Wockhardt, expressed pride in the findings from early treatments, where critically ill patients who received Zaynich showed remarkable recovery rates. In addition to Zaynich, Wockhardt is testing Nafithromycin, an oral treatment for community-acquired bacterial pneumonia that has demonstrated a high success rate in initial trials.However, the road to progress is fraught with challenges, not least of which is an environment where the pharmaceutical industry often prioritizes revenue-generating drugs for chronic conditions over those for antibiotics. Anand Anandkumar, CEO of Bugworks Research, highlights the urgent need for more financial support and innovation in this field, reflecting a broader trend where infection resistance is sidelined.Recent studies from the Indian Council of Medical Research (ICMR) indicate troubling trends in bacterial resistance across the nation, singling out E.coli and Klebsiella pneumoniae as particularly concerning pathogens. Alarmingly, some antibiotics are proving ineffective against these strains, leading doctors to become increasingly concerned over the reduced options available to treat such infections. The widespread use of broad-spectrum antibiotics, often prescribed without adequate diagnostic data, exacerbates this situation by allowing drug-resistant bacteria to thrive.To address this pressing matter, experts emphasize the need for urgent reforms in antibiotic prescribing within Indian healthcare systems, focusing on narrow-spectrum alternatives and improving sanitation and hospital practices. The complexity of combating antimicrobial resistance calls for a united front, incorporating public health education and robust infrastructure improvements to minimize infection risks.The arrival of new antibiotics is cause for cautious optimism, yet experts like Dr. Kamini Walia from ICMR stress the importance of embracing responsible antibiotic stewardship to ensure the longevity and effectiveness of these breakthrough medications. Without a holistic approach that combines innovation with improved healthcare policies, the daunting prospect of untreatable infections looms ominously on the horizon.
